SAVIMS

This site is still under construction - more information to follow

C-19 Vaccine South Africa Fund To Protect Pharm Companies

Summary

South Africa’s introduction of the Covid-19 Vaccine Injury No-Fault Compensation Scheme aims to shield pharmaceutical companies from liability related to coronavirus vaccines, making the country more appealing for vaccine deals. Despite challenges in the vaccine rollout, the scheme, published by the Department of Health on April 15, 2021, includes a panel led by a retired judge to adjudicate claims, with compensation regulations set by the finance minister. South Africa has ordered 30 million doses each of the Johnson & Johnson (J&J) and Pfizer vaccines, but only inoculated 290,000 healthcare workers with the J&J vaccine due to a temporary suspension over rare blood clot concerns. The suspension, along with a prior halt on AstraZeneca’s vaccine due to its ineffectiveness against the B.1.351 variant, has slowed the rollout. The no-fault fund seeks to expedite vaccine acquisitions and support the goal of vaccinating 40 million people by February 2022, amid delays caused by manufacturers’ demands for government guarantees and indemnities.

Tags

Scroll to Top